Is Inosine Dimepranol Acedoben compatible with breastfeeding? Do we have alternatives for Inosine Dimepranol Acedoben?

Inosine Dimepranol Acedoben

June 10, 2018 (Low Risk)

A nucleoside derivative with antiviral properties. There is little published data on this product and little evidence of its efficacy as an antiviral (You 2015, Kinghorn 1992, Mindel 1989, Pachuta 1974) and even less as an immunostimulant (Smith 2015, Trentham 199).
It has been used with poor results in infections due to herpes simplex, genital warts, colds, subacute sclerosing panencephalitis, chronic fatigue syndrome and rheumatoid arthritis.
Administered orally every 4 to 6 hours for 2 to 4 weeks.

Since the last update we have not found published data on its excretion in breastmilk.

The little known pharmacokinetic data (high molecular weight and short half-life) make transfer to milk in significant amounts unlikely.

The manufacturer indicates its use in children, even from the first month of life. Possible side effects are usually mild and infrequent.

As there is less published information than for other drugs from the same group, safer known alternatives may be preferable during the neonatal period and in case of prematurity.

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • Inosine Pranobex
  • Isoprinosine
  • Methisoprinol

Writings

  • Ινοσίνη πρανομπεξ (Greek)
  • Инозин Димепранол Ацедобен (Cyrillic)
  • Inosine Acédobène Dimépranol (French)
  • C10 H12 N4 O5 : C14 H22 N2 O4 (1:3) (Molecular formula)
  • Inosine 2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3) (Chemical name)
  • J05AX05 (ATC Code/s)

Drug trade names

References

  1. You Y, Wang L, Li Y, Wang Q, Cao S, Tu Y, Li S, Bai L, Lu J, Wei Z, Chen W, Hao F. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015Abstract
  2. Smith ME, Haney E, McDonagh M, Pappas M, Daeges M, Wasson N, Fu R, Nelson HD. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015Abstract
  3. Aventis. Isoprinosine Ficha técnica. 2014 Full text (in our servers)
  4. IMB. Isoprinosine. Drug Summary. 2014 Full text (in our servers)
  5. Kinghorn GR, Woolley PD, Thin RN, De Maubeuge J, Foidart JM, Engst R. Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection. Genitourin Med. 1992Abstract
  6. Trentham DE. Immunotherapy and other novel therapies. Curr Opin Rheumatol. 1991Abstract
  7. Mindel A, Carney O, Sonnex C, Freris M, Patou G, Williams P. Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex. Genitourin Med. 1989Abstract
  8. Pachuta DM, Togo Y, Hornick RB, Schwartz AR, Tominaga S. Evaluation of isoprinosine in experimental human rhinovirus infection. Antimicrob Agents Chemother. 1974Abstract